Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Formycon Strengthens Biosimilars Portfolio With Athos Assets

Deal Will Be Paid For With A Consideration Worth Approximately €650m

Executive Summary

Formycon and Athos have merged aspects of their biosimilar development activities as part of a long-term strategic partnership.

You may also be interested in...



Coherus And Formycon’s Ranibizumab Rapidly Ramps Up In US

Formycon has reported positive uptake trends in the US for its Coherus-partnered ranibizumab biosimilar at the end of 2023, mirroring recent success in the UK with marketing ally Teva.

Formycon Submits Eylea Biosimilar For European Approval Following Strong Q3

Formycon has submitted its aflibercept candidate for European Medicines Agency consideration, following an incredibly strong Q3 which has put the company on track for a promising future.

Cimerli Success Drives Strong H1 At Formycon

Formycon delivered a strong H1, as its Lucentis biosimilar made significant strides in the US market. The company now anticipates the highest revenue in its history for 2023.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

GB151778

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel